OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the U.S. Food and Drug Administration (FDA).
Checked against the public recordLast updated Jan 10, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- OSI Pharmaceuticals
- Interventions being studied
- Drug: Tarceva (erlotinib HCl, OSI-774 )
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
* Clinical diagnosis of stage IIIB or IV non-small cell lung cancer. * Must have evidence of disease (clinical or radiological). * Have failed 1 but no more than 2 prior chemotherapy regimens, have recovered from any side effects and have not had any chemotherapy for at least 21 days. * If the patient has had surgery, the surgery was at least 2 weeks ago. * Patients whose cancer has spread to their brain or central nervous system are eligible, providing that they have been on stable dose of steroids for at least 4 weeks and are free of symptoms. * If the patient received radiation therapy, treatment was at least 4 weeks ago.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Chicago Medical CenterChicago, Illinois
- University of WashingtonSeattle, Washington
- Centro Medico ConfidenceBuenos Aires, CP
- Hospital BritanicoBuenos Aires
- Hospital Interzonal de Agudos EvitaBuenos Aires
- Instituto Alexander flemingBuenos Aires
- Hospital Churruca ViscaBuenos Aires
- Instituto Oncologico Angel RoffoCapital Federal
- Hospital ItalianoCapital Federal
- Canberra Hospital- AustraliaWoden, Australian Capital Territory
- Prince of Wales HospitalRandwick, New South Wales
- Newcastle Mater Misericordiae HospitalWaratah, New South Wales
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 10, 2018. Always confirm current availability with the study team.